Riluzole, neuroprotection and amyotrophic lateral sclerosis

Current Medicinal Chemistry

Volumn 17, Issue 18, 2010, Pages 1942-1959

  Cheah, B C ^a   Vucic, S ^a   Krishnan, A V ^a   Kiernan, M C ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Amyotrophic lateral sclerosis; Clinical trial; Excitotoxicity; Glutamate; Motor neuron; Motor neuron disease; Riluzole

Indexed keywords

4 AMINOBUTYRIC ACID; CALCIUM CHANNEL BLOCKING AGENT; GLUTAMIC ACID; RILUZOLE; SODIUM CHANNEL BLOCKING AGENT; VOLTAGE GATED SODIUM CHANNEL;

ABDOMINAL PAIN; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; CIRCUMORAL PARESTHESIA; CLINICAL TRIAL; DEGENERATIVE DISEASE; DIARRHEA; DRUG BIOAVAILABILITY; DRUG STRUCTURE; EXCITOTOXICITY; GABAERGIC SYSTEM; HEADACHE; HEPATITIS; HUMAN; HYPERTENSION; JAUNDICE; LIVER FUNCTION TEST; MOTONEURON; MOTOR NEURON DISEASE; NAUSEA; NERVE DEGENERATION; NEUROPROTECTION; NEUROTRANSMITTER RELEASE; NONHUMAN; OUTCOME ASSESSMENT; OXIDATIVE STRESS; PATHOPHYSIOLOGY; RHINITIS; SIDE EFFECT; SODIUM CONDUCTANCE; SOMNOLENCE; TREATMENT OUTCOME;

AMYOTROPHIC LATERAL SCLEROSIS; CLINICAL TRIALS AS TOPIC; HUMANS; NEUROPROTECTIVE AGENTS; RILUZOLE;

EID: 77953503937     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986710791163939     Document Type: Article

References (220)

1. Charcot, J.M.; Joffroy, A. Deux cas d'atrophie musculaire progressive avec lesions de la substance grise et des faisceaux anterolateraux de la moelle epiniere. Arch. Physiol., 1869, 2, 354.
2. Kiernan, M.C. Motor neurone disease: a pandora's box. Med. J. Aust., 2003, 178, 311-2.
3. Eisen, A.; Kim, S.; Pant, B. Amyotrophic lateral sclerosis (ALS): a phylogenetic disease of the corticomotoneuron? Muscle Nerve, 1992, 15, 219-24.
4. Ringel, S.P.; Murphy, J.R.; Alderson, M.K.; Bryan, W, England, J.D.; Miller, R.G.; Petajan, J.H.; Smith, S.A.; Roelofs, R.I.; Ziter, F.; Lee, M.Y.; Brinkmann, J.R.; Almada, A.; Gappmaier, E.; Graves, J.; Herbelin, L.; Mendoza, M.; Mylar, D.; Smith, P.; Yu, P. The natural history of amyotrophic lateral sclerosis. Neurology, 1993, 43, 1316-22.
5. Shoesmith, C.L.; Findlater, K.; Rowe, A.; Strong, M.J. Prognosis of amyotrophic lateral sclerosis with respiratory onset. J. Neurol. Neurosurg. Psychiatry, 2007, 78, 629-31.
6. Caroscio, J.T.; Mulvihill, M.N.; Sterling, R.; Abrams, B. Amyotrophic lateral sclerosis. Its natural history. Neurol. Clin., 1987, 5, 1-8.
7. Gros-Louis, F.; Gaspar, C.; Rouleau, G.A. Genetics of familial and sporadic amyotrophic lateral sclerosis. Biochim. Biophys. Acta, 2006, 1762, 956-72.
8. Pasinelli, P.; Brown, R.H. Molecular biology of amyotrophic lateral sclerosis: insights from genetics. Nat. Rev. Neurosci., 2006, 7, 710-23.
9. Patel, S.A.; Maragakis, N.J. Amyotrophic lateral sclerosis: pathogenesis, differential diagnoses, and potential interventions. J. Spinal Cord Med., 2002, 25, 262-73.
10. Neusch, C.; Bahr, M.; Schneider-Gold, C. Glia cells in amyotrophic lateral sclerosis: new clues to understanding an old disease? Muscle Nerve, 2007, 35, 712-24.
11. Gonzalez de Aguilar, J.L.; Echaniz-Laguna, A.; Fergani, A.; Rene, F.; Meininger, V.; Loeffler, JP, Dupuis, L. Amyotrophic lateral sclerosis: all roads lead to Rome. J. Neurochem., 2007, 101, 1153-60.
12. Hasegawa, M.; Arai, T.; Nonaka, T.; Kametani, F.; Yoshida, M.; Hashizume, Y.; Beach, T.G.; Buratti, E.; Baralle, F.; Morita, M.; Nakano, I.; Oda, T.; Tsuchiya, K.; Akiyama, H. Phosphorylated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Ann. Neurol., 2008, 64, 60-70.
13. Doble, A. The pharmacology and mechanism of action of riluzole. Neurology, 1996, 47, S233-41.
14. Heath, P.R.; Shaw, P.J. Update on the glutamatergic neurotransmitter system and the role of excitotoxicity in amyotrophic lateral sclerosis. Muscle Nerve, 2002, 26, 438-58.
15. Foran, E.; Trotti, D. Glutamate transporters and the excitotoxic path to motor neuron degeneration in amyotrophic lateral sclerosis. Antioxid. Redox. Signal, 2009, 11, 1587-602.
16. Tanaka, K.; Watase, K.; Manabe, T.; Yamada K.;, Watanabe M.; Takahashi K.; Iwama H.; Nishikawa T.; Ichihara N.; Kikuchi T.; Okuyama S.; Kawashima N.; Hori S.; Takimoto M.; Wada K. Epilepsy and exacerbation of brain injury in mice lacking the glutamate transporter GLT-1. Science, 1997, 276, 1699-1702.
17. Laake, J.H.; Slyngstad, T.A.; Haug, F.M.; Ottersen, O.P. Glutamine from glial cells is essential for the maintenance of the nerve terminal pool of glutamate: immunogold evidence from hippocampal slice cultures. J. Neurochem., 1995, 65, 871-81.
18. Rothstein, J.D.; Tsai, G.; Kuncl, R.W.; Clawson, L.; Cornblath, D.R.; Drachman, D.B.; Pestronk, A.; Stauch, B.L.; J.T. C. Abnormal excitatory amino acid metabolism in amyotrophic lateral sclerosis. Ann. Neurol., 1990, 28, 18-25.
19. Yin, H.Z.; Tang, D.T.; Weiss, J.H. Intrathecal infusion of a Ca2+-permeable AMPA channel blocker slows loss of both motor neurons and of the astrocyte glutamate transporter, GLT-1 in a mutant SOD1 rat model of ALS. Exp. Neurol., 2007, 207, 177-85.
20. Rothstein, J.D.; Van Kammen, M.; Levey, A.I.; Martin, L.J.; Kuncl, R.W. Selective loss of glial glutamate transporter GLT-1 in amyotrophic lateral sclerosis. Ann. Neurol., 1995, 38, 73-84.
21. Rothstein, J.D.; Martin, L.J.; Kuncl, R.W. Decreased glutamate transport by the brain and spinal cord in amyotrophic lateral sclerosis. N. Engl. J. Med., 1992, 326, 1464-68.
22. Rothstein, J.D.; Dykes-Hoberg, M.; Pardo, C.A.; Bristol, L.A.; Jin, L.; Kuncl, R.W.; Kanai, Y.; Hediger, M.A.; Wang, Y.; Schielke, J.P.; Welty, D.F. Knockout of glutamate transporters reveals a major role for astroglial transport in excitotoxicity and clearance of glutamate. Neuron, 1996, 16, 675-86.
23. Swanson, R.A.; Liu, J.; Miller, J.W.; Rothstein, J.D.; Farrell, K.; A. Stein, B, Longuemare, M.C. Neuronal regulation of glutamate transporter subtype expression in astrocytes. J. Neurosci., 1997, 17, 932-40.
24. Rao, S.D.; Yin, H.Z.; Weiss, J.H. Disruption of glial glutamate transport by reactive oxygen species produced in motor neurons. J. Neurosci., 2003, 23, 2627-33.
25. Hollmann, M.; Hartley, M.; Heinemann, S. Ca2+ permeability of KA-AMPA--gated glutamate receptor channels depends on subunit composition. Science, 1991, 252, 851-3.
26. Van Damme, P.; Van Den Bosch, L.; Van Houtte, E.; Callewaert, G.; Robberecht, W. GluR2-dependent properties of AMPA receptors determine the selective vulnerability of motor neurons to excitotoxicity. J. Neurophysiol., 2002, 88, 1279-87.
27. Corona, J.C.; Tapia, R. AMPA receptor activation, but not the accumulation of endogenous extracellular glutamate, induces paralysis and motor neuron death in rat spinal cord in vivo. J. Neurochem., 2004, 89, 988-97.
28. Zhao, P.; Ignacio, S.; Beattie, E.C.; Abood, M.E. Altered presymptomatic AMPA and cannabinoid receptor trafficking in motor neurons of ALS model mice: implications for excitotoxicity. Eur. J. Neurosci., 2008, 27, 572-9.
29. Maria, E.; Alexianu, B-K.H. The role of calcium-binding proteins in selective motoneuron vulnerability in amyotrophic lateral sclerosis. Ann. Neurol., 1994, 36, 846-58.
30. Ince, P.; Stout, N.; Shaw, P.; Slade, J.; Hunziker, W.; Heizmann, C.W.; Baimbridge, K.G. Parvalbumin and calbindin d-28k in the human motor system and in motor neuron disease. Neuropathol. Appl. Neurobiol., 1993, 19, 291-9.
31. Roy, J.; Minotti, S.; Dong, L.; Figlewicz, D.A.; Durham, H.D. Glutamate potentiates the toxicity of mutant Cu/Zn-superoxide dismutase in motor neurons by postsynaptic calcium-dependent mechanisms. J. Neurosci., 1998, 18, 9673-84.
32. Rosen, D.R.; Siddique, T.; Patterson, D.; Figlewicz, D.A.; Sapp, P.; Hentati, A.; Donaldson, D.; Goto, J.; O'Regan, J.P.; Deng, H.X.; Rahmani, Z.; Krizus, A.; McKenna-Yasek, D.; Cayabyab, A.; Gaston, S.; Berger, R.; Tanzi, R.E.; Halperin, J.J.; Herzfeldt, B.; Van den Bergh, R.; Hung, W.; Bird, T.; Deng, G.; Mulder, D.W.; Smyth, C.; Laing, N.G.; Soriano, E.; Pericak-Vance, M.A.; Haines, J.; Rouleau, G.A.; Gusella, J.S.; Horvitz, H.R.; Brown, R.H.Jr. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature, 1993, 362, 59-62.
33. Fenton, H.J.H. Oxidation of tartaric acid in presence of iron. J. Chem. Soc, Trans, 1894, 65, 899-910.
34. Barber, S.C.; Mead, R.J.; Shaw, P.J. Oxidative stress in ALS: a mechanism of neurodegeneration and a therapeutic target. Biochim. Biophys. Acta., 2006, 1762, 1051-67.
35. Gurney, M.E.; Haifeng, P.; Chiu, A.Y.; Dal Canto, M.C.; Polchow, C.Y.; Alexander, D.D.; Caliendo, J.; Hentati, A.; Kwon, Y.W.; Deng, H.; Chen, W.; Zhai, P.; Sufit, R.L.; Siddique, T. Motor neuron degeneration in mice that express a human Cu/Zn superoxide dismutase mutation. Science, 1994, 264, 1772-5.
36. Gurney, M.E.; Cutting, F.B.; Zhai, P.; Doble, A.; Taylor, C.P.; Andrus, P.K.; Hall, E.D. Benefit of vitamin E, riluzole, and gabapentin in a transgenic model of familial amyotrophic lateral sclerosis. Ann. Neurol., 1996, 39, 147-57.
37. Gurney, M.E.; Fleck, T.J.; Himes, C.S.; Hall, E.D. Riluzole preserves motor function in a transgenic model of familial amyotrophic lateral sclerosis. Neurology, 1998, 50, 62-6.
38. Waibel, S.; Reuter, A.; Malessa, S.; Blaugrund, E.; Ludolph, A.C. Rasagiline alone and in combination with riluzole prolongs survival in an ALS mouse model. J. Neurol., 2004, 251, 1080-4.
39. Volterra, A.; Trotti, D.; Racagni, G. Glutamate uptake is inhibited by arachidonic acid and oxygen radicals via two distinct and additive mechanisms. Mol. Pharmacol., 1994, 46, 986-92.
40. Trotti, D.; Danbolt, N.C.; Volterra, A. Glutamate transporters are oxidant-vulnerable: a molecular link between oxidative and excitotoxic neurodegeneration? Trends Pharmacol. Sci., 1998, 19, 328-34.
41. Afifi, A.K.; Aleu, F.P.; Goodgold, J.; MacKay, B. Ultrastructure of atrophic muscle in amyotrophic lateral sclerosis. Neurology, 1966, 16, 475-81.
42. Kong, J.; Xu, Z. Massive mitochondrial degeneration in motor neurons triggers the onset of amyotrophic lateral sclerosis in mice expressing a mutant SOD1. J. Neurosci., 1998, 18, 3241-50.
43. De Vos, K.J.; Chapman, A.L.; Tennant, M.E.; Manser, C.; Tudor, E.L.; Lau, K.F.; Brownlees, J.; Ackerley, S.; Shaw, P.J.; McLoughlin, D.M.; Shaw, C.E.; Leigh, P.N.; Miller, C.C.; Grierson, A.J. Familial amyotrophic lateral sclerosis-linked SOD1 mutants perturb fast axonal transport to reduce axonal mitochondria content. Hum. Mol. Genet., 2007, 16, 2720-8.
44. Lemasters, J.J.; Nieminen, A.L.; Qian, T.; Trost, L.C.; Elmore, S.P.; Nishimura, Y.; Crowe, R.A.; Cascio, W.E.; Bradham, C.A.; Brenner, D.A.; Herman, B. The mitochondrial permeability transition in cell death: A common mechanism in necrosis, apoptosis and autophagy. Biochim. Biophys. Acta, 1998, 1366, 177-96.
45. Buki, A.; Okonkwo, D.O.; Wang, K.K.W.; Povlishock, J.T. Cytochrome c release and caspase activation in traumatic axonal injury. J. Neurosci., 2000, 20, 2825-34.
46. Liu, X.; Kim, C.N.; Yang, J.; Jemmerson, R.; Wang, X. Induction of apoptotic program in cell-free extracts: requirement for dATP and cytochrome c. Cell, 1996, 86, 147-57.
47. Martin, L.J.; Gertz, B.; Pan, Y.; Price, A.C.; Molkentin, J.D.; Chang, Q. The mitochondrial permeability transition pore in motor neurons: involvement in the pathobiology of ALS mice. Exp. Neurol. 2009, 218, 333-46.
48. Babcock, D.F.; Herrington, J.; Goodwin, P.C.; Park, Y.B.; Hille, B. Mitochondrial participation in the intracellular Ca2+ network. J. Cell. Biol., 1997, 136, 833-44.
49. Jaiswal, M.K.; Keller, B.U. Cu/Zn superoxide dismutase typical for familial amyotrophic lateral sclerosis increases the vulnerability of mitochondria and perturbs Ca2+ homeostasis in SOD1 G93A mice. Mol. Pharmacol., 2009, 75, 478-89.
50. McGeer, P.L.; McGeer, E.G. Inflammatory processes in amyotrophic lateral sclerosis. Muscle Nerve, 2002, 26, 459-70.
51. Boillee, S.; Yamanaka, K.; Lobsiger, C.S.; Copeland, N.G.; Jenkins, N.A.; Kassiotis, G.; Kollias, G.; Cleveland, D.W. Onset and progression in inherited ALS determined by motor neurons and microglia. Science, 2006, 312, 1389-92.
52. Mitchell, R.M.; Freeman, W.M.; Randazzo, W.T.; Stephens, H.E.; Beard, J.L.; Simmons, Z.; Connor, J.R. A CSF biomarker panel for identification of patients with amyotrophic lateral sclerosis. Neurology, 2009, 72, 14-9.
53. Yasojima, K.; Tourtellotte, W.W.; McGeer, E.G.; McGeer, P.L. Marked increase in cyclooxygenase-2 in ALS spinal cord: implications for therapy. Neurology, 2001, 57, 952-6.
54. Gong, Y.H.; Parsadanian, A.S.; Andreeva, A.; Snider, W.D.; Elliott, J.L. Restricted expression of G86R Cu/Zn superoxide dismutase in astrocytes results in astrocytosis but does not cause motoneuron degeneration. J. Neurosci., 2000, 20, 660-5.
55. Van Damme, P.; Bogaert, E.; Dewil, M.; Hersmus, N.; Kiraly, D.; Scheveneels, W.; Bockx, I.; Braeken, D.; Verpoorten, N.; Verhoeven, K.; Timmerman, V.; Herijgers, P.; Callewaert, G.; Carmeliet, P.; Van Den Bosch, L.; Robberecht, W. Astrocytes regulate GluR2 expression in motor neurons and their vulnerability to excitotoxicity. Proc. Natl. Acad. Sci. U.S.A., 2007, 104, 14825-30.
56. Vargas, M.R.; Johnson, D.A.; Sirkis, D.W.; Messing, A.; Johnson, J.A. Nrf2 activation in astrocytes protects against neurodegeneration in mouse models of familial amyotrophic lateral sclerosis. J. Neurosci., 2008, 28, 13574-81.
57. Ackerley, S.; Grierson, A.J.; Brownlees, J.; Thornhill, P.; Anderton, B.H.; Leigh, P.N.; Shaw, C.E.; Miller, C.C. Glutamate slows axonal transport of neurofilaments in transfected neurons. J. Cell Biol., 2000, 150, 165-76.
58. Puls, I.; Jonnakuty, C.; LaMonte, B.H.; Holzbaur, E.L.; Tokito, M.; Mann, E.; Floeter, M.K.; Bidus, K.; Drayna, D.; Oh, S.J.; Brown, R.H.Jr.; Ludlow, C.L.; Fischbeck, K.H. Mutant dynactin in motor neuron disease. Nat. Genet., 2003, 33, 455-6.
59. Winton, M.J.; Igaz, L.M.; Wong, M.M.; Kwong, L.K.; Trojanowski, J.Q.; Lee, V.M. Disturbance of nuclear and cytoplasmic tar DNA-binding protein (TDP-43) induces disease-like redistribution, sequestration, and aggregate formation. J. Biol. Chem., 2008, 283, 13302-9.
60. Kabashi, E.; Valdmanis, P.N.; Dion, P.; Spiegelman, D.; McConkey, B.J.; Vande Velde, C.; Bouchard, J.P.; Lacomblez, L.; Pochigaeva, K.; Salachas, F.; Pradat, P.F.; Camu, W.; Meininger, V.; Dupre, N.; Rouleau, G.A. TARDBP mutations in individuals with sporadic and familial amyotrophic lateral sclerosis. Nat. Genet., 2008, 40, 572-4.
61. Tagawa, A.; Tan, C.F.; Kikugawa, K.; Fukase, M.; Nakano, R.; Onodera, O.; Nishizawa, M.; Takahashi, H. Familial amyotrophic lateral sclerosis: a SOD1-unrelated Japanese family of bulbar type with bunina bodies and ubiquitin-positive skein-like inclusions in lower motor neurons. Acta Neuropathol., 2007, 113, 205-11.
62. Shibata, N.; Hirano, A.; Kobayashi, M.; Siddique, T.; Deng, H.X.; Hung, W.Y.; Kato, T.; Asayama, K. Intense superoxide dismutase-1 immunoreactivity in intracytoplasmic hyaline inclusions of familial amyotrophic lateral sclerosis with posterior column involvement. J. Neuropathol. Exp. Neurol., 1996, 55, 481-90.
63. Vance, C.; Rogelj, B.; Hortobágyi, T.; De Vos, K.J.; Nishimura, A.L.; Sreedharan, J.; Hu, X.; Smith, B.; Ruddy, D.; Wright, P.; Ganesalingam, J.; Williams, K.L.; Tripathi, V.; Al-Saraj, S.; AlChalabi, A.; Leigh, P.N.; Blair, I.P.; Nicholson, G.; de Belleroche, J.; Gallo, J.M.; Miller, C.C.; Shaw, C.E. Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science, 2009, 323, 1208-11.
64. Kwiatkowski, T.J.Jr.; Bosco, D.A.; Leclerc, A.L.; Tamrazian, E.; Vanderburg, C.R.; Russ, C.; Davis, A.; Gilchrist, J.; Kasarskis, E.J.; Munsat, T.; Valdmanis, P.; Rouleau, G.A.; Hosler, B.A.; Cortelli, P.; de Jong, P.J.; Yoshinaga, Y.; Haines, J.L.; Pericak-Vance, M.A.; Yan, J.; Ticozzi, N.; Siddique, T.; McKenna-Yasek, D.; Sapp, P.C.; Horvitz, H.R.; Landers, J.E.; Brown, R.H.Jr. Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science, 2009, 323, 1205-8.
65. Hartl, F.U.; Hayer-Hartl, M. Molecular chaperones in the cytosol: from nascent chain to folded protein. Science, 2002, 295, 1852-8.
66. Kabashi, E.; Durham, H.D. Failure of protein quality control in amyotrophic lateral sclerosis. Biochim. Biophys. Acta, 2006, 1762, 1038-50.
67. Kalmar, B.; Novoselov, S.; Gray, A.; Cheetham, M.E.; Margulis, B.; Greensmith, L. Late stage treatment with arimoclomol delays disease progression and prevents protein aggregation in the SOD1 mouse model of ALS. J. Neurochem., 2008, 107, 339-50.
68. Okado-Matsumoto, A.; Fridovich, I. Amyotrophic lateral sclerosis: a proposed mechanism. Proc. Natl. Acad. Sci. U.S.A., 2002, 99, 9010-4.
69. Hofmann, A.W. Ueber die einwirkung des phosphorpentachlorids auf senföle und verwandte körper. Berichte der deutschen chemischen Gesellschaft., 1879, 12, 1126-30.
70. Domino, E.F.; Unna, K.R.; Kerwin, J. Pharmacological properties of benzazoles. I. Relationship between structure and paralyzing action. J. Pharmacol. Exp. Ther. 1952, 105, 486-97.
71. Mizoule, J.; Meldrum, B.; Mazadier, M.; Croucher, M.; Ollat, C.; Uzan, A.; Legrand, J.J.; Gueremy, C.; Le Fur, G. 2-amino-6-trifluoromethoxy benzothiazole, a possible antagonist of excitatory amino acid neurotransmission: anticonvulsant properties. Neuropharmacology, 1985, 24, 767-73.
72. Benavides, J.; Camelin, J.C.; Mitrani, N.; Flamand, F.; Uzan, A.; Legrand, J.J.; Gueremy, C.; Le Fur, G. 2-amino-6-trifluoromethoxy benzothiazole, a possible antagonist of excitatory amino acid neurotransmission: biochemical properties. Neuropharmacology, 1985, 24, 1085-92.
73. Rana, A.; Siddiqui, N.; Kahn, S.A. Benzothiazoles: a new profile of biological activities. Indian J. Pharm. Sci., 2007, 69, 10-7.
74. Jordan, A.D.; Luo, C.; Reitz, A.B. Efficient conversion of substituted aryl thioureas to 2-aminobenzothiazoles using benzyltrimethylammonium tribromide. J. Org. Chem., 2003, 68, 8693-6.
75. Yagupol'skii, L.M.; Gandel'sman L.Z. Diazastyryls with substituents containing fluorine. Chem. Abs., 1964, 60, 692.
76. Bensimon, G.; Lacomblez, L.; Meininger, V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/riluzole study group. N. Engl. J. Med., 1994, 330, 585-91.
77. Meininger, V.; Lacomblez, L.; Salachas, F. What has changed with riluzole? J. Neurol., 2000, 247, 19-22.
78. Jimonet, P.; Audiau, F.; Barreau, M.; Blanchard, J.C.; Boireau, A.; Bour, Y.; Coleno, M.A.; Doble, A.; Doerflinger, G.; Huu, C.D.; Donat, M.H.; Duchesne, J.M.; Ganil, P.; Guérémy, C.; Honor, E.; Just, B.; Kerphirique, R.; Gontier, S.; Hubert, P.; Laduron, P.M.; Le Blevec, J.; Meunier, M.; Miquet, J.M.; Nemecek, C.; Mignani, S. Riluzole series. Synthesis and in vivo antiglutamate activity of 6-substituted-2-benzothiazolamines and 3-substituted-2-imino-benzothiazolines. J. Med. Chem., 1999, 42, 2828-43.
79. Hays, S.J.; Rice, M.J.; Ortwine, D.F.; Johnson, G.; Schwarz, R.D.; Boyd, D.K.; Copeland, L.F.; Vartanian, M.G.; Boxer, P.A. Substituted 2-benzothiazolamines as sodium flux inhibitors: quantitative structure-activity relationships and anticonvulsant activity. J. Pharm. Sci., 1994, 83, 1425-32.
80. Dessi, F.; Ben-Ari, Y.; Charriaut-Marlangue C. Riluzole prevents anoxic injury in cultured cerebellar granule neurons. Eur. J. Pharmacol., 1993, 250, 325-8.
81. Nogradi, A.; Szabo, A.; Pinter, S.; Vrbova, G. Delayed riluzole treatment is able to rescue injured rat spinal motoneurons. Neuroscience, 2007, 144, 431-8.
82. Bergerot, A.; Shortland, P.J.; Anand, P.; Hunt, S.P.; Carlstedt, T. Co-treatment with riluzole and GDNF is necessary for functional recovery after ventral root avulsion injury. Exp. Neurol., 2004, 187, 359-66.
83. Nogradi, A.; Vrbova, G. The effect of riluzole treatment in rats on the survival of injured adult and grafted embryonic motoneurons. Eur. J. Neurosci., 2001, 13, 113-8.
84. Lips, J.; de Haan, P.; Bodewits, P.; Vanicky, I.; Dzoljic, M.; Jacobs, M.J.; Kalkman, C.J. Neuroprotective effects of riluzole and ketamine during transient spinal cord ischemia in the rabbit. Anesthesiology, 2000, 93, 1303-11.
85. Bae, H.J.; Lee, Y.S.; Kang, D.W.; Koo, J.S.; Yoon, B.W.; Roh, J.K. Neuroprotective effect of low dose riluzole in gerbil model of transient global ischemia. Neurosci. Lett., 2000, 294, 29-32.
86. Lang-Lazdunski, L.; Heurteaux, C.; Mignon, A.; Mantz, J.; Widmann, C.; Desmonts, J.; Lazdunski, M. Ischemic spinal cord injury induced by aortic cross-clamping: prevention by riluzole. Eur. J. Cardiothorac. Surg., 2000, 18, 174-81.
87. Lang-Lazdunski, L.; Heurteaux, C.; Dupont, H.; Widmann, C.; Lazdunski, M. Prevention of ischemic spinal cord injury: comparative effects of magnesium sulfate and riluzole. J. Vasc. Surg., 2000, 32, 179-89.
88. Siniscalchi, A.; Zona, C.; Sancesario, G.; D'Angelo, E.; Zeng, Y.C.; Mercuri, N.B.; Bernardi, G. Neuroprotective effects of riluzole: an electrophysiological and histological analysis in an in vitro model of ischemia. Synapse, 1999, 32, 147-52.
89. Lang-Lazdunski, L.; Heurteaux, C.; Vaillant, N.; Widmann, C.; Lazdunski, M. Riluzole prevents ischemic spinal cord injury caused by aortic crossclamping. J. Thorac. Cardiovasc. Surg., 1999, 117, 881-9.
90. Ettaiche, M.; Fillacier, K.; Widmann, C.; Heurteaux, C.; Lazdunski, M. Riluzole improves functional recovery after ischemia in the rat retina. Invest. Ophthalmol. Vis. Sci., 1999, 40, 729-36.
91. Wahl, F.; Allix, M.; Plotkine, M.; Boulu, R.G. Effect of riluzole on focal cerebral ischemia in rats. Eur. J. Pharmacol., 1993, 230, 209-14.
92. Pratt, J.; Rataud, J.; Bardot, F.; Roux, M.; Blanchard, J.C.; Laduron, P.M.; Stutzmann, J.M. Neuroprotective actions of riluzole in rodent models of global and focal cerebral ischaemia. Neurosci. Lett., 1992, 140, 225-30.
93. Malgouris, C.; Bardot, F.; Daniel, M.; Pellis, F.; Rataud, J.; Uzan, A.; Blanchard, J.C.; Laduron, P.M. Riluzole, a novel antiglutamate, prevents memory loss and hippocampal neuronal damage in ischemic gerbils. J. Neurosci., 1989, 9, 3720-7.
94. Wang, J.; Dib, M.; Lenoir, M.; Vago, P.; Eybalin, M.; Hameg, A.; Pujol, R.; Puel, J.L. Riluzole rescues cochlear sensory cells from acoustic trauma in the guinea-pig. Neuroscience, 2002, 111, 635-48.
95. Centonze, D.; Calabresi, P.; Pisani, A.; Marinelli, S.; Marfia, G.A.; Bernardi, G. Electrophysiology of the neuroprotective agent riluzole on striatal spiny neurons. Neuropharmacology, 1998, 37, 1063-70.
96. Cheramy, A.; Barbeito, L.; Godeheu, G.; Glowinski, J. Riluzole inhibits the release of glutamate in the caudate nucleus of the cat in vivo. Neurosci. Lett. 1992, 147, 209-12.
97. Bezard, E.; Stutzmann, J.M.; Imbert, C.; Boraud, T.; Boireau, A.; Gross, C.E. Riluzole delayed appearance of parkinsonian motor abnormalities in a chronic MPTP monkey model. Eur. J. Pharmacol., 1998, 356, 101-4.
98. Barneoud, P.; Mazadier, M.; Miquet, J.M.; Parmentier, S.; Dubedat, P.; Doble, A.; Boireau A. Neuroprotective effects of riluzole on a model of parkinson's disease in the rat. Neuroscience, 1996, 74, 971-83.
99. Landwehrmeyer, G.B.; Dubois, B.; de Yébenes, J.G.; Kremer, B.; Gaus, W.; Kraus, P.H.; Przuntek, H.; Dib, M.; Doble, A.; Fischer, W.; Ludolph, A.C.; European Huntington's Disease Initiative Study Group. Riluzole in Huntington's disease: a 3-year, randomized controlled study. Ann. Neurol., 2007, 62, 262-72.
100. Bensimon, G.; Ludolph, A.; Agid, Y.; Vidailhet, M.; Payan, C.; Leigh, P.N.; for the NSG. Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study. Brain, 2009, 132, 156-71.
101. Estevez, A.G.; Stutzmann, J.M.; Barbeito, L. Protective effect of riluzole on excitatory amino acid-mediated neurotoxicity in motoneuron-enriched cultures. Eur. J. Pharmacol., 1995, 280, 47-53.
102. Koh, J.Y.; Kim, D.K.; Hwang, J.Y.; Kim, Y.H.; Seo, J.H. Antioxidative and proapoptotic effects of riluzole on cultured cortical neurons. J. Neurochem., 1999, 72, 716-23.
103. Malgouris, C.; Daniel, M.; Doble, A. Neuroprotective effects of riluzole on n-methyl-d-aspartateor veratridine-induced neurotoxicity in rat hippocampal slices. Neurosci. Lett., 1994, 177, 95-9.
104. Debono, M.W.; Le Guern, J.; Canton, T.; Doble, A.; Pradier, L. Inhibition by riluzole of electrophysiological responses mediated by rat kainate and NMDA receptors expressed in xenopus oocytes. Eur. J. Pharmacol. 1993, 235, 283-9.
105. Lamanauskas, N.; Nistri, A. Riluzole blocks persistent Na+ and Ca2+ currents and modulates release of glutamate via presynaptic NMDA receptors on neonatal rat hypoglossal motoneurons in vitro. Eur. J. Neurosci., 2008, 27, 2501-14.
106. Prakriya, M.; Mennerick, S. Selective depression of low-release probability excitatory synapses by sodium channel blockers. Neuron, 2000, 26, 671-82.
107. Siniscalchi, A.; Bonci, A.; Mercuri, N.B.; Bernardi, G. Effects of riluzole on rat cortical neurones: an in vitro electrophysiological study. Br. J. Pharmacol., 1997, 120, 225-30.
108. Albo, F.; Pieri, M.; Zona, C. Modulation of AMPA receptors in spinal motor neurons by the neuroprotective agent riluzole. J. Neurosci. Res., 2004, 78, 200-7.
109. Fumagalli, E.; Funicello, M.; Rauen, T.; Gobbi, M.; Mennini, T. Riluzole enhances the activity of glutamate transporters GLAST, GLT1 and EAAC1. Eur. J. Pharmacol., 2008, 578, 171-6.
110. Martin, D.; Thompson, M.A.; Nadler, J.V. The neuroprotective agent riluzole inhibits release of glutamate and aspartate from slices of hippocampal area CA1. Eur. J. Pharmacol., 1993, 250, 473-6.
111. Jehle, T.; Bauer, J.; Blauth, E.; Hummel, A.; Darstein, M.; Freiman, T.M.; Feuerstein, T.J. Effects of riluzole on electrically evoked neurotransmitter release. Br. J. Pharmacol., 2000, 130, 1227-34.
112. LoPachin, R.M.; Lehning, E.J. Mechanism of calcium entry during axon injury and degeneration. Toxicol. Appl. Pharmacol., 1997, 143, 233-44.
113. Yoo, M.H.; Hyun, H.J.; Koh, J.Y.; Yoon, Y.H. Riluzole inhibits VEGF-induced endothelial cell proliferation in vitro and hyper-oxia-induced abnormal vessel formation in vivo. Invest. Ophthalmol. Vis. Sci., 2005, 46, 4780-7.
114. Stevenson, A.; Yates, D.M.; Manser, C.; De Vos, K.J.; Vagnoni, A.; Leigh, P.N.; McLoughlin, D.M.; Miller, C.C. Riluzole protects against glutamate-induced slowing of neurofilament axonal transport. Neurosci. Lett., 2009, 454, 161-4.
115. Wang, S.J.; Wang, K.Y.; Wang, W.C. Mechanisms underlying the riluzole inhibition of glutamate release from rat cerebral cortex nerve terminals (synaptosomes). Neuroscience, 2004, 125, 191-201.
116. Stys, P.K.; Ransom, B.R.; Waxman, S.G. Effects of polyvalent cations and dihydropyridine calcium channel blockers on recovery of CNS white matter from anoxia. Neurosci. Lett., 1990, 115, 293-299.
117. Stys, P.K.; Waxman, S.G.; Ransom, BR. Na+-Ca2+ exchanger mediates Ca2+ influx during anoxia in mammalian central nervous system white matter. Ann. Neurol., 1991, 30, 375-80.
118. Waxman, S.G.; Black, J.A.; Ransom, B.R.; Stys, P.K. Anoxic injury of rat optic nerve: ultrastructural evidence for coupling between Na+ influx and Ca2+-mediated injury in myelinated CNS axons. Brain. Res., 1994, 644, 197-204.
119. Hebert, T.; Drapeau, P.; Pradier, L.; Dunn, R.J. Block of the rat brain IIa sodium channel alpha subunit by the neuroprotective drug riluzole. Mol. Pharmacol., 1994, 45, 1055-60.
120. Kononenko, N.I.; Shao, L.R.; Dudek, F.E. Riluzole-sensitive slowly inactivating sodium current in rat suprachiasmatic nucleus neurons. J. Neurophysiol., 2004, 91, 710-8.
121. Urbani, A, Belluzzi, O. Riluzole inhibits the persistent sodium current in mammalian CNS neurons. Eur. J. Neurosci., 2000, 12, 3567-74.
122. Butterworth, J.F. 4th, Strichartz, G.R. Molecular mechanisms of local anesthesia: a review. Anesthesiology, 1990, 72, 711-34.
123. Benoit, E.; Escande, D. Riluzole specifically blocks inactivated na channels in myelinated nerve fibre. Pflügers Arch., 1991, 419, 603-609.
124. Mestre, M.; Djellas, Y.; Carriot, T.; Cavero, I. Frequency-independent blockade of cardiac Na+ channels by riluzole: comparison with established anticonvulsants and class I anti-arrhythmics. Fundam. Clin. Pharmacol., 2000, 14, 107-17.
125. Wang, Y.J.; Lin, M.W.; Lin, A.A.; Wu, S.N. Riluzole-induced block of voltage-gated Na+ current and activation of BKCa channels in cultured differentiated human skeletal muscle cells. Life. Sci., 2008, 82, 11-20.
126. Obrenovitch, T.P. Amyotrophic lateral sclerosis, excitotoxicity and riluzole. Trends. Pharmacol. Sci., 1998, 19, 9-11.
127. Jimonet, P.; Barreau, M.; Blanchard, J.C.; Boireau, A.; Doble, A.; Laduron, P.; Lavayre, J.; Malgouris, C.; Piot, O.; Pratt, J.; Rataud, J.; Reibaud, M.; Mignani, S.; Stutzmann, J.M. Synthesis, anticonvulsant and neuroprotective activities of RP 66055, a riluzole derivative. Bioorg. Med. Chem. 1994, 2, 793-8.
128. He, Y.; Benz, A.; Fu, T.; Wang, M.; Covey, D.F.; Zorumski, C.F.; Mennerick, S. Neuroprotective agent riluzole potentiates postsynaptic GABAA receptor function. Neuropharmacology, 2002, 42, 199-209.
129. Mantz, J.; Laudenbach, V.; Lecharny, J.B.; Henzel, D.; Desmonts, J.M. Riluzole, a novel antiglutamate, blocks gaba uptake by striatal synaptosomes. Eur. J. Pharmacol., 1994, 257, R7-8.
130. Stutzmann, J.M.; Lucas, M.; Blanchard, J.C.; Laduron, P.M. Riluzole, a glutamate antagonist, enhances slow wave and REM sleep in rats. Neurosci. Lett., 1988, 88, 195-200.
131. Stefan, K.; Kunesch, E.; Benecke, R.; Classen, J. Effects of riluzole on cortical excitability in patients with amyotrophic lateral sclerosis. Ann. Neurol., 2001, 49, 536-9.
132. Noh, K.M.; Hwang, J.Y.; Shin, H.C.; Koh, J.Y. A novel neuroprotective mechanism of riluzole: direct inhibition of protein kinase c. Neurobiol. Dis., 2000, 7, 375-83.
133. Doble, A.; Hubert, J.P.; Blanchard, J.C. Pertussis toxin pretreatment abolishes the inhibitory effect of riluzole and carbachol on d-(3h)aspartate release from cultured cerebellar granule cells. Neurosci. Lett., 1992, 140, 251-4.
134. Azbill, R.D.; Mu, X.; Springer, J.E. Riluzole increases high-affinity glutamate uptake in rat spinal cord synaptosomes. Brain. Res., 2000, 871, 175-80.
135. Bruno, R.; Vivier, N.; Montay, G.; Le Liboux, A.; Powe, L.K.; Delumeau, J.C.; Rhodes, G.R. Population pharmacokinetics of riluzole in patients with amyotrophic lateral sclerosis. Clin. Pharmacol. Ther., 1997, 62, 518-26.
136. Le Liboux, A.; Cachia, J.P.; Kirkesseli, S.; Gautier, J.Y.; Guimart, C.; Montay, G.; Peeters, P.A.; Groen, E.; Jonkman, J.H.; Wemer, J. A comparison of the pharmacokinetics and tolerability of riluzole after repeat dose administration in healthy elderly and young volunteers. J. Clin. Pharmacol., 1999, 39, 480-6.
137. Sanderink, G.J.; Bournique, B.; Stevens, J.; Petry, M.; Martinet, M. Involvement of human CYP1A isoenzymes in the metabolism and drug interactions of riluzole in vitro. J. Pharmacol. Exp. Ther., 1997, 282, 1465-72.
138. Groeneveld, G.J.; van Kan, H.J.; Lie-A-Huen, L.; Guchelaar, H.J.; van den Berg, L.H. An association study of riluzole serum concentration and survival and disease progression in patients with ALS. Clin. Pharmacol. Ther., 2008, 83, 718-22.
139. Schwenkreis, P.; Liepert, J.; Witscher, K.; Fischer, W.; Weiller, C.; Malin, J.P.; Tegenthoff, M. Riluzole suppresses motor cortex facilitation in correlation to its plasma level. A study using transcranial magnetic stimulation. Exp. Brain Res., 2000, 135, 293-9.
140. Bensimon, G.; Doble, A. The tolerability of riluzole in the treatment of patients with amyotrophic lateral sclerosis. Expert. Opin. Drug Saf., 2004, 3, 525-34.
141. Groeneveld, G.J.; van Kan, H.J.; Torano, J.S.; Veldink, J.H.; Guchelaar, H.J.; Wokke, J.H.; van den Berg, L.H. Inter-and intraindividual variability of riluzole serum concentrations in patients with ALS. J. Neurol. Sci., 2001, 191, 121-5.
142. Le Liboux, A.; Lefebvre, P.; Le Roux, Y.; Truffinet, P.; Aubeneau, M.; Kirkesseli, S.; Montay, G. Single-and multiple-dose pharma-cokinetics of riluzole in white subjects. J. Clin. Pharmacol., 1997, 37, 820-7.
143. Colovic, M.; Zennaro, E.; Caccia, S. Liquid chromatographic assay for riluzole in mouse plasma and central nervous system tissues. J. Chromatogr. B Analyt. Technol. Biomed. Life. Sci., 2004, 803, 305-309.
144. Lacomblez, L.; Bensimon, G.; Leigh, P.N.; Guillet, P.; Meininger, V. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic lateral sclerosis/riluzole study group II. Lancet, 1996, 347, 1425-31.
145. Riviere, M.; Meininger, V.; Zeisser, P.; Munsat, T. An analysis of extended survival in patients with amyotrophic lateral sclerosis treated with riluzole. Arch. Neurol., 1998, 55, 526-8.
146. Bensimon, G.; Lacomblez, L.; Delumeau, J.C.; Bejuit, R.; Truffinet, P.; Meininger, V. A study of riluzole in the treatment of advanced stage or elderly patients with amyotrophic lateral sclerosis. J. Neurol., 2002, 249, 609-15.
147. Miller, R.G.; Mitchell, J.D.; Lyon, M.; Moore, D.H. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst. Rev., 2007, 1, CD001447.
148. Remy, A.J.; Camu, W.; Ramos, J.; Blanc, P.; Larrey, D. Acute hepatitis after riluzole administration. J. Hepatol., 1999, 30, 527-30.
149. Castells, L.I.; Gamez, J.; Cervera, C.; Guardia, J. Icteric toxic hepatitis associated with riluzole. Lancet, 1998, 351, 648.
150. Schoenfeld, D.A.; Cudkowicz, M.E. Design of phase II ALS clinical trials. Amyotroph. Lateral Scler., 2008, 9, 16-23.
151. Stommel, E.W.; Cohen, J.A.; Fadul, C.E.; Cogbill, C.H.; Graber, D.J.; Kingman, L.; Mackenzie, T.; Channon Smith, J.Y.; Harris, B.T. Efficacy of thalidomide for the treatment of amyotrophic lateral sclerosis: a phase II open label clinical trial. Amyotroph. Lateral Scler., 2009, 10, 393-404.
152. Simmons, Z. Can we eliminate placebo in ALS clinical trials? Muscle Nerve, 2009, 39, 861-5.
153. Qureshi, M.; Schoenfeld, D.A.; Paliwal, Y.; Shui, A.; Cudkowicz, M.E. The natural history of ALS is changing: improved survival. Amyotroph. Lateral Scler., 2009, 10, 324-31.
154. Kaufmann, P.; Thompson, J.L.; Levy, G.; Buchsbaum, R.; Shefner, J.; Krivickas, L.S.; Katz, J.; Rollins, Y.; Barohn, R.J.; Jackson, C.E.; Tiryaki, E.; Lomen-Hoerth, C.; Armon, C.; Tandan, R.; Rudnicki, S.A.; Rezania, K.; Sufit, R.; Pestronk, A.; Novella, S.P.; Heiman-Patterson, T.; Kasarskis, E.J.; Pioro, E.P.; Montes, J.; Arbing, R.; Vecchio, D.; Barsdorf, A.; Mitsumoto, H.; Levin, B.; QALS Study Group. Phase II trial of CoQ10 for ALS finds insufficient evidence to justify phase III. Ann. Neurol., 2009, 66, 235-44.
155. Gordon, P.H.; Cheung, Y.K.; Levin, B.; Andrews, H.; Doorish, C.; Macarthur, R.B.; Montes, J.; Bednarz, K.; Florence, J.; Rowin, J.; Boylan, K.; Mozaffar, T.; Tandan, R.; Mitsumoto, H.; Kelvin, E.A.; Chapin, J.; Bedlack, R.; Rivner, M.; McCluskey, L.F.; Pestronk, A.; Graves, M.; Sorenson, E.J.; Barohn, R.J.; Belsh, J.M.; Lou, J.S.; Levine, T.; Saperstein, D.; Miller, R.G.; Scelsa, S.N.; Combination Drug Selection Trial Study Group. A novel, efficient, randomized selection trial comparing combinations of drug therapy for ALS. Amyotroph. Lateral Scler., 2008, 9, 212-22.
156. Meininger, V.; Asselain, B.; Guillet, P.; Leigh, P.N.; Ludolph, A.; Lacomblez, L.; Robberecht, W. Pentoxifylline in ALS: a doubleblind, randomized, multicenter, placebo-controlled trial. Neurology, 2006, 66, 88-92.
157. Gordon, P.H.; Moore, D.H.; Miller, R.G.; Florence, J.M.; Verheijde, J.L.; Doorish, C.; Hilton, J.F.; Spitalny, G.M.; MacArthur, R.B.; Mitsumoto, H.; Neville, H.E.; Boylan, K.; Mozaffar, T.; Belsh, J.M.; Ravits, J.; Bedlack, R.S.; Graves, M.C.; McCluskey, L.F.; Barohn, R.J.; Tandan, R.; Western ALS Study Group. Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial. Lancet Neurol., 2007, 6, 1045-53.
158. Cudkowicz, M.E.; Shefner, J.M.; Schoenfeld, D.A.; Brown, R.H. Jr.; Johnson, H.; Qureshi, M.; Jacobs, M.; Rothstein, J.D.; Appel, S.H.; Pascuzzi, R.M.; Heiman-Patterson, T.D.; Donofrio, P.D.; David, W.S.; Russell, J.A.; Tandan, R.; Pioro, E.P.; Felice, K.J.; Rosenfeld, J.; Mandler, R.N.; Sachs, G.M.; Bradley, W.G.; Raynor, E.M.; Baquis, G.D.; Belsh, J.M.; Novella, S.; Goldstein, J.; Hulihan, J.; Northeast ALS Consortium. A randomized, placebocontrolled trial of topiramate in amyotrophic lateral sclerosis. Neurology, 2003, 61, 456-64.
159. Ross, E. Unapproved drug use: compassionate or cause for concern? Lancet Neurol., 2009, 8, 136-7.
160. Benatar, M. Lost in translation: treatment trials in the SOD1 mouse and in human ALS. Neurobiol. Dis., 2007, 26, 1-13.
161. Kriz, J.; Gowing, G.; Julien, J.P. Efficient three-drug cocktail for disease induced by mutant superoxide dismutase. Ann. Neurol., 2003, 53, 429-36.
162. Zhang, W.; Narayanan, M.; Friedlander, R.M. Additive neuroprotective effects of minocycline with creatine in a mouse model of ALS. Ann. Neurol., 2003, 53, 267-70.
163. Feng, H.L.; Leng, Y.; Ma, C.H.; Zhang, J.; Ren, M.; Chuang, D.M. Combined lithium and valproate treatment delays disease onset, reduces neurological deficits and prolongs survival in an amyotrophic lateral sclerosis mouse model. Neuroscience, 2008, 155, 567-72.
164. Milane, A.; Fernandez, C.; Vautier, S.; Bensimon, G.; Meininger, V.; Farinotti, R. Minocycline and riluzole brain disposition: interactions with p-glycoprotein at the blood-brain barrier. J. Neurochem., 2007, 103, 164-73.
165. Milane, A.; Tortolano, L.; Fernandez, C.; Bensimon, G.; Meininger, V.; Farinotti, R. Brain and plasma riluzole pharmacokinetics: effect of minocycline combination. J. Pharm. Pharmaceut. Sci., 2009, 12, 209-17.
166. Cedarbaum, J.M.; Stambler, N.; Malta, E.; Fuller, C.; Hilt, D.; Thurmond, B.; Nakanishi, A. The ALSFRS-r: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS study group (phase III). J. Neurol. Sci., 1999, 169, 13-21.
167. Bhatt, J.M.; Gordon, P.H. Current clinical trials in amyotrophic lateral sclerosis. Expert Opin. Investig. Drugs, 2007, 16, 1197-1207.
168. Sorensen, E.J. Assessment of strength measurements. Amyotroph. Lateral Scler. Other Motor Neuron Disord., 2004, 5, S1, 86-89.
169. Traynor, B.J.; Zhang, H.; Shefner, J.M.; Schoenfeld, D.; Cudkowicz, M.E.; Consortium, N. Functional outcome measures as clinical trial endpoints in ALS. Neurology, 2004, 63, 1933-5.
170. Shefner, J.M. Designing clinical trials in amyotrophic lateral sclerosis. Phys. Med. Rehabil. Clin. N. Am., 2008, 19, 495-508.
171. Gordon, P.H.; Corcia, P.; Lacomblez, L.; Pochigaeva, K.; Abitbol, J.L.; Cudkowicz, M.; Leigh, P.N.; Meininger, V. Defining survival as an outcome measure in amyotrophic lateral sclerosis. Arch. Neurol., 2009, 66, 758-61.
172. Shefner, J.M. Designing clinical trials in amyotrophic lateral sclerosis. Phys. Med. Rehabil. Clin. N. Am., 2008, 19, 495-508.
173. Beasley, W.C. Quantitative muscle testing: principles and applications to research and clinical services. Arch. Phys. Med. Rehabil., 1961, 42, 398-425.
174. Chen, W.C.; Cheng, H.H.; Huang, C.J.; Chou, C.T.; Liu, S.I.; Chen, I.S.; Hsu, S.S.; Chang, H.T.; Huang, J.K.; Jan, CR. Effect of riluzole on Ca2+ movement and cytotoxicity in madin-darby canine kidney cells. Hum. Exp. Toxicol., 2006, 25, 461-9.
175. Jan, C.R.; Lu, Y.C.; Jiann, B.P.; Chang, H.T.; Huang, J.K. Effect of riluzole on cytosolic Ca2+ increase in human osteosarcoma cells. Pharmacology, 2002, 66, 120-7.
176. Wang, J.L.; Lee, K.C.; Tang, K.Y.; Lu, T.; Chang, C.H.; Chow, C.K.; Chen, W.C.; Su, W.; Law, Y.P.; Jan, C.R. Effect of the neuroprotective agent riluzole on intracellular Ca2+ levels in IMR32 neuroblastoma cells. Arch. Toxicol., 2001, 75, 214-20.
177. Storch, A.; Burkhardt, K.; Ludolph, A.C.; Schwarz, J. Protective effects of riluzole on dopamine neurons: involvement of oxidative stress and cellular energy metabolism. J. Neurochem., 2000, 75, 2259-69.
178. Meininger, V.; Drory, V.E.; Leigh, P.N.; Ludolph, A.; Robberecht, W.; Silani, V. Glatiramer acetate has no impact on disease progression in ALS at 40 mg/day: a doubleblind, randomized, multicentre, placebo-controlled trial. Amyotroph. Lateral Scler., 2009, 10, 378-83.
179. Heemskerk, J.; Tobin, A.J.; Ravina, B. From chemical to drug: neurodegeneration drug screening and the ethics of clinical trials. Nat. Neurosci., 2002, 5, 1027-9.
180. Swash, M. Learning from failed trials in ALS. Lancet Neurol., 2007, 6, 1034-5.
181. Schnabel, J. Neuroscience: standard model. Nature, 2008, 454, 682-5.
182. Zhu, S.; Stavrovskaya, I.G.; Drozda, M.; Kim, B.Y.; Ona, V.; Li, M.; Sarang, S.; Liu, A.S.; Hartley, D.M.; Wu, D.C.; Gullans, S.; Ferrante, R.J.; Przedborski, S.; Kristal, B.S.; Friedlander, R.M. Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice. Nature, 2002, 417, 74-8.
183. Klivenyi, P.; Ferrante, R.J.; Matthews, R.T.; Bogdanov, M.B.; Klein, A.M.; Andreassen, O.A.; Mueller, G.; Wermer, M.; Kaddurah-Daouk, R.; Beal, M.F. Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis. Nat. Med., 1999, 5, 347-50.
184. Shefner, J.M.; Cudkowicz, M.E.; Schoenfeld, D.; Conrad, T.; Taft, J.; Chilton, M.; Urbinelli, L.; Qureshi, M.; Zhang, H.; Pestronk, A.; Caress, J.; Donofrio, P.; Sorenson, E.; Bradley, W.; Lomen-Hoerth, C.; Pioro, E.; Rezania, K.; Ross, M.; Pascuzzi, R.; Heiman-Patterson, T.; Tandan, R.; Mitsumoto, H.; Rothstein, J.; Smith-Palmer, T.; MacDonald, D.; Burke, D.; NEALS Consortium. A clinical trial of creatine in ALS. Neurology, 2004, 63, 1656-61.
185. Groeneveld, G.J.; Veldink, J.H.; van der Tweel, I.; Kalmijn, S.; Beijer, C.; de Visser, M.; Wokke, J.H.J.; Franssen, H.; van den Berg, L.H. A randomized sequential trial of creatine in amyotrophic lateral sclerosis. Ann. Neurol., 2003, 53, 437-45.
186. Vucic, S.; Howells, J.; Trevillion, L.; Kiernan, M.C. Assessment of cortical excitability using threshold tracking techniques. Muscle Nerve, 2006, 33, 477-86.
187. Vucic, S.; Kiernan, M.C. Novel threshold tracking techniques suggest that cortical hyperexcitability is an early feature of motor neuron disease. Brain, 2006, 129, 2436-46.
188. Eisen, A.; Pant, B.; Stewart, H. Cortical excitability in amyotrophic lateral sclerosis: a clue to pathogenesis. Can. J. Neurol. Sci., 1993, 20, 11-6.
189. Vucic, S.; Nicholson, G.A.; Kiernan, M.C. Cortical hyperexcitability may precede the onset of familial amyotrophic lateral sclerosis. Brain, 2008, 131, 1540-50.
190. Zanette, G.; Tamburin, S.; Manganotti, P.; Refatti, N.; Forgione, A.; Rizzuto, N. Different mechanisms contribute to motor cortex hyperexcitability in amyotrophic lateral sclerosis. Clin. Neurophysiol., 2002, 113, 1688-97.
191. Pieri, M.; Carunchio, I.; Curcio, L.; Mercuri, N.B.; Zona, C. Increased persistent sodium current determines cortical hyperexcitability in a genetic model of amyotrophic lateral sclerosis. Exp. Neurol. 2009, 215, 368-79.
192. Bulatko, A.K.; Greeff, N.G. Functional availability of sodium channels modulated by cytosolic free Ca2+ in cultured mammalian neurons (N1E-115). J. Physiol., 1995, 484, 307-12.
193. Tamura, N.; Kuwabara, S.; Misawa, S.; Kanai, K.; Nakata, M.; Sawai, S.; Hattori, T. Increased nodal persistent Na+ currents in human neuropathy and motor neuron disease estimated by latent addition. Clin. Neurophysiol., 2006, 117, 2451-8.
194. Priori, A.; Cinnante, C.; Pesenti, A.; Carpo, M.; Cappellari, A.; Nobile-Orazio, E.; Scarlato, G.; Barbieri, S. Distinctive abnormalities of motor axonal strength-duration properties in multifocal motor neuropathy and in motor neurone disease. Brain, 2002, 125, 2481-90.
195. Mogyoros, I.; Kiernan, M.C.; Burke, D.; Bostock, H. Strengthduration properties of sensory and motor axons in amyotrophic lateral sclerosis. Brain, 1998, 121, 851-9.
196. Vucic, S.; Kiernan, M.C. Axonal excitability properties in amyotrophic lateral sclerosis. Clin. Neurophysiol., 2006, 117, 1458-66.
197. Kanai, K.; Kuwabara, S.; Misawa, S.; Tamura, N.; Ogawara, K.; Nakata, M.; Sawai, S.; Hattori, T.; Bostock, H. Altered axonal excitability properties in amyotrophic lateral sclerosis: impaired potassium channel function related to disease stage. Brain, 2006, 129, 953-62.
198. Zona, C.; Pieri, M.; Carunchio, I. Voltage-dependent sodium channels in spinal cord motor neurons display rapid recovery from fast inactivation in a mouse model of amyotrophic lateral sclerosis. J. Neurophysiol., 2006, 96, 3314-22.
199. Stys, P.K.; Waxman, S.G.; Ransom, B.R. Ionic mechanisms of anoxic injury in mammalian CNS white matter: role of Na+ channels and Na+-Ca2+ exchanger. J. Neurosci., 1992, 12, 430-9.
200. Stys, P.K.; Waxman, S.G.; Ransom, B.R. Reverse operation of the Na+-Ca2+ exchanger mediates Ca2+ influx during anoxia in mammalian CNS white matter. Ann. N. Y. Acad. Sci., 1991, 639, 328-332.
201. Waxman, S.G. Mechanisms of disease: sodium channels and neuroprotection in multiple sclerosis-current status. Nat. Clin. Pract. Neurol., 2008, 4, 159-69.
202. Smith, K.J.; Kapoor, R.; Hall, S.M.; Davies M. Electrically active axons degenerate when exposed to nitric oxide. Ann. Neurol., 2001, 49, 470-6.
203. Kapoor, R.; Davies, M.; Blaker, P.A.; Hall, S.M.; Smith, K.J. Blockers of sodium and calcium entry protect axons from nitric ox-ide-mediated degeneration. Ann. Neurol., 2003, 53, 174-80.
204. Bechtold, D.A.; Miller, S.J.; Dawson, A.C.; Sun, Y.; Kapoor, R.; Berry, D.; Smith, K.J. Axonal protection achieved in a model of multiple sclerosis using lamotrigine. J. Neurol., 2006, 253, 1542-1551.
205. Bechtold, D.A.; Kapoor, R.; Smith, K.J. Axonal protection using flecainide in experimental autoimmune encephalomyelitis. Ann. Neurol., 2004; 55, 607-16.
206. Bechtold, D.A.; Yue, X.; Evans, R.M.; Davies, M.; Gregson, N.A.; Smith, K.J. Axonal protection in experimental autoimmune neuritis by the sodium channel blocking agent flecainide. Brain, 2005, 128, 18-28.
207. Trapp, B.D.; Stys, P.K. Virtual hypoxia and chronic necrosis of demyelinated axons in multiple sclerosis. Lancet Neurol., 2009, 8, 280-91.
208. Vucic, S.; Krishnan, A.V.; Kiernan, M.C. Fatigue and activity dependent changes in axonal excitability in amyotrophic lateral sclerosis. J. Neurol. Neurosurg. Psychiatry, 2007, 78, 1202-8.
209. Ellis, D.Z.; Rabe, J.; Sweadner, K.J. Global loss of Na+/K+-ATPase and its nitric oxide-mediated regulation in a transgenic mouse model of amyotrophic lateral sclerosis. J. Neurosci., 2003, 23, 43-51.
210. Heemskerk, J. High throughput drug screening. Amyotroph. Lateral Scler. Other. Motor. Neuron Disord., 2004, 5, S1, 19-21.
211. Rothstein, J.D.; Patel, S.; Regan, M.R.; Haenggeli, C.; Huang, Y.H.; Bergles, D.E.; Jin, L, Dykes Hoberg, M.; Vidensky, S.; Chung, D.S.; Toan, S.V.; Bruijn, L.I.; Su, Z.Z.; Gupta, P.; Fisher, P.B. -lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. Nature, 2005, 433, 73-7.
212. Wegorzewska, I.; Bell, S.; Cairns, N.J.; Miller, T.M.; Baloh, R.H. TDP-43 mutant transgenic mice develop features of ALS and frontotemporal lobar degeneration. Proc. Natl. Acad. Sci. U.S.A., 2009, 106, 18809-14.
213. Stefani, A.; Spadoni, F.; Bernardi, G. Differential inhibition by riluzole, lamotrigine, and phenytoin of sodium and calcium currents in cortical neurons: implications for neuroprotective strategies. Exp. Neurol., 1997, 147, 115-22.
214. Huang, C-S.; Song, J-H.; Nagata, K.; Yeh, J.Z.; Narahashi, T. Effects of the neuroprotective agent riluzole on the high voltage-activated calcium channels of rat dorsal root ganglion neurons. J. Pharmacol. Exp. Ther., 1997, 282, 1280-90.
215. Spadoni, F.; Hainsworth, A.H.; Mercuri, N.B.; Caputi, L.; Martella, G.; Lavaroni, F.; Bernardi, G.; Stefani, A. Lamotrigine derivatives and riluzole inhibit iNap in cortical neurons. Neuroreport, 2002, 13, 1167-70.
216. Zona, C.; Siniscalchi, A.; Mercuri, N.B.; Bernardi, G. Riluzole interacts with voltage-activated sodium and potassium currents in cultured rat cortical neurons. Neuroscience, 1998, 85, 931-8.
217. Lamas, J.A.; Romero, M.; Reboreda, A.; Sanchez, E.; Ribeiro, S.J. A riluzole and valproate-sensitive persistent sodium current contributes to the resting membrane potential and increases the excitability of sympathetic neurones. Pflügers Arch., 2009, 458, 589-99.
218. Beltran-Parrazal, L, Charles, A. Riluzole inhibits spontaneous Ca2+ signaling in neuroendocrine cells by activation of K+ channels and inhibition of Na+ channels. Br. J. Pharmacol., 2003, 140, 881-8.
219. Irifune, M.; Kikuchi, N.; Saida, T.; Takarada, T.; Shimizu, Y.; Endo, C.; Morita, K.; Dohi, T.; Sato, T.; Kawahara, M. Riluzole, a glutamate release inhibitor, induces loss of righting reflex, antinociception, and immobility in response to noxious stimulation in mice. Anesth. Analg., 2007, 104, 1415-21.
220. Keita, H.; Boczkowski, J.; Samb, A.; Lanone, S.; Lang-Lazdunski, L.; Rouelle, D.; Desmonts, J.M.; Mantz, J. Anesthetic concentrations of riluzole inhibit neuronal nitric oxide synthase activity, but not expression, in the rat hippocampus. Brain Res., 2000, 881, 237-40.